Skip to main content

Table 2 Covariate adjusted interaction tests between tamoxifen treatment efficacy according to recurrence-free interval and different cell proliferation markers analyzed as binary factor. Co-variables included age (≥ 65 versus < 65), grade (grade 3 versus grade 1–2), tumor size (T3–4 versus T1-T2), HER2 status (positive versus negative), and PgR status (positive versus negative)

From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Variable levels HR (95% CI) for tamoxifen vs control
(total follow-up)
Interaction
p-value
HR (95% CI) for tamoxifen vs control
(follow-up truncated at 6 yearsa)
Interaction
p-value
Mitotic count <  8/ 2mm2 0.38 (0.20–0.70) 0.13 0.24 (0.12–0.49) 0.03
≥ 8/ 2mm2 0.70 (0.40–1.23) 0.64 (0.35–1.17)
Cyclin D1 ≤ 50% 0.48(0.25–0.93) 0.48  
>  50% 0.66 (0.34–1.29)
Ki67 <  5% 0.50 (0.26–0.98) 0.97
≥ 5% 0.50 (0.26–0.93)
CCND1 probeset 1 log 2copy number ratio <  0 0.39 (0.18–0.86) 0.33
>  0 0.62 (0.18–1.07)
CCND1 probeset 2 log2 copy number ratio <  0 0.32 (0.16–0.61) 0.04
>  0 0.81 (0.44–1.52)
  1. aAnalysis performed for mitotic count only, since failure of proportional hazard assumption was observed
\